- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03292991
REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)
Study Overview
Status
Conditions
Detailed Description
All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.
Primary objective:
To observe the safety of SIR-Spheres® microspheres therapy (SIRT)by,
- Adverse events and serious adverse events (non-specific and radiation specific)
- Changes in liver function parameters
- To observe the efficacy of SIR-Spheres® microspheres therapy by, assessing the best overall response rate after SIRT
Secondary objectives:
To observe the efficacy of SIRT by,
- Overall survival (OS)
- Overall/objective response rate (ORR)
- Time-to-progression
- Time-to-liver progression
- Progression-free survival
To observe the changes in clinical presentation after SIRT by,
- ECOG score
- Child-Pugh score
- Percentage of subjects with down-staging or down-sizing of treated lesion to resection, transplantation, or radiofrequency ablation (RFA)
To observe the practice pattern of SIRT by,
- Median dosage (GBq)
- Number of SIRT sessions received by subjects
Exploratory objectives:
To explore prognostic factors for disease progression after SIRT by comparing the following parameters:
- Number of tumors in subjects prior to SIRT
- Median tumor size in subjects prior to SIRT
- Location of tumor in subjects treated with SIRT (hepatic segment or lobe)
- Number of prior TACE treatment in subjects
- Antiviral therapy subjects HCC
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Rheun-Chuan Lee, M.D.
- Phone Number: 3069 +886-2-28712121
- Email: vghtpeyttrium90@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hospital
-
Contact:
- Rheun-Chuan Lee, M.D.
- Phone Number: 3069 +886-2-28712121
- Email: vghtpeyttrium90@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria, Patients who meet all inclusion criteria will be included:
- Males or non-pregnant females, at least 18 years of age (inclusive).
- Patients with clinically confirmed hepatocellular carcinoma (HCC) OR adenocarcinoma of colon/rectum with liver metastasis.
- Patients with liver dominant disease.
- Tumor burden ≤ 70% of total liver volume.
- HCC patients with child-Pugh Score class A or B.
- HCC patients with Barcelona-Clinic Liver Cancer (BCLC) stage A-C.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
- Patients who are unsuitable for resection or immediate liver transplantation or who cannot be optimally treated with local ablation.
- Patients who have provided written informed consent.
Exclusion Criteria, Patients who meet any exclusion criteria will be excluded:
- Patients known to be hypersensitive to any component of study product.
- Female patients who are pregnant or lactating. Women of child bearing potential who disagree to practice medically recognized birth control methods throughout the study (from Screening to approximately 6 months post SIRT). Medically recognized birth control methods include hormonal contraceptives, intrauterine device/IUD, barrier device, or abstinence. With the exception of women who had been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient), or one year post-menopausal.
Withdrawal criteria:
- Patients consent withdrawal.
- Lost to follow-up for 2 consecutive visits.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.
Time Frame: 6 months
|
Toxicity will be accessed according to CTCAE v4.03.
The incidence of adverse events will be summarized and the change in baseline liver function will be assessed by paired t-test or Wilcoxon signed rank test.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 1 year
|
Overall survival (OS) is determined for all enrolled subjects from Day 0 to the date of death or last contact.
|
1 year
|
Overall Response Rate per RECIST 1.1 and mRECIST
Time Frame: 1 year
|
Liver tumor assessments for CRC will be evaluated by RECIST v1.1; and tumor assessments for HCC will be evaluated by mRECIST. - Objective Response Rate is defined as the proportion of subjects with tumor size reduction (i.e. the combined proportion of subjects with CR and PR) from Day 0 until documented tumor progression. |
1 year
|
Time-to-progression per RECIST 1.1 and mRECIST
Time Frame: 1 year
|
The time-to-progression (TTP) is calculated by the time from Day 0 to the date of disease progression (PD).
|
1 year
|
Time-to-liver progression per RECIST 1.1 and mRECIST
Time Frame: 1 year
|
The time-to-liver progression is calculated by the time from Day 0 to the date of tumor progression (PD) in intrahepatic lesions.
|
1 year
|
Progression-free survival
Time Frame: 1 year
|
Progression free survival (PFS) is determined for all enrolled patients from Day 0 until tumor progression or patient death.
|
1 year
|
Liver resection rate
Time Frame: 1 year
|
Patients will be assessed for suitability for liver resection every study visit during the study period.
|
1 year
|
Liver transplantation rate
Time Frame: 1 year
|
Patients will be assessed for suitability for liver transplantation every study visit during the study period.
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rheun-Chuan Lee, M.D., Taipei Veterans General Hospital, Taiwan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- QCR14021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States